Team PHenomenal Hope to host first symposium on PH research

Abstracts for the Boston event can be submitted until Aug. 1

Andrea Lobo avatar

by Andrea Lobo |

Share this article:

Share article via email
A speaker leads a meeting at a conference.

Team PHenomenal Hope will host its inaugural symposium — PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH — on Dec. 15 in Boston, allowing renowned experts, young researchers, and healthcare providers to share efforts on pulmonary hypertension (PH) clinical research and care.

“Team PHenomenal Hope has grown exponentially in recent years and is excited to bring forward this new research symposium with the support of our premier sponsor and others to collaborate and focus on patient-centered research,” Harrison Farber, MD, chair of the board of directors at Team PHenomenal Hope, said in a press release.

A feature of PH is high blood pressure in the blood vessels that supply the lungs, called pulmonary arteries. The nonprofit advocacy organization Team PHenomenal Hope seeks to provide funding for medical research toward new treatments or a cure for and implement programs and services to improve care and patients’ quality of life.

Recommended Reading
An illustration of a hand with money is shown.

Research Proposals Being Accepted for PHenomenal Impact Fund

Team PHenomenal Hope symposium focusing on research

The symposium will feature oral presentations, panel discussions with experts, and poster sessions to encourage interaction among participants. Abstracts should focus on original research, recognizing unmet needs in research and patient care. They can be submitted until Aug. 1.

“We are seeking to offer a unique event that will focus on topics unrelated to medications, procedures, and direct PAH pathophysiology [disease processes]. Submitted abstracts should focus on unique research and topics that highlight caring for the whole patient, and exploring the potential for positive outcomes through a better understanding of disease modification and clinical trial design,” the organization explains.

Topics can include diversity and inclusion in PH registries and clinical trials, clinical trial design and data improvement, understanding disease modifying agents, strategies for patient engagement, and the relation between pulmonary arterial hypertension and substance abuse. The topics and speakers will be released by Oct. 1.

Omni Boston Hotel at the Seaport is the official host of the event. The hotel has partnered with the organization to offer discounts to participants.

“Team PHenomenal Hope has identified a new opportunity for the PH community that aims to inspire continued innovation and collaboration, and we are proud to be the premier sponsor of this research symposium,” said Samuele Butera, president of U.S. Pulmonary Hypertension and Retina at the Janssen Pharmaceutical Companies of Johnson & Johnson. “At Janssen, we are deeply committed to supporting scientific advancement and revolutionizing the patient experience.”

A Conversation With Rare Disease Advocates